MRNA Moderna
WatchlistModerna News
Moderna | 8-K: Chief Commercial Officer Arpa Garay Cancelled the Garay 10b5-1 Plan on November 6, 2023
Moderna | 8-K: Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Moderna | 8-K: Moderna Statement on Anticipated 2023 COVID-19 Sales
Moderna | 8-K: Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Moderna | 8-K: Moderna Reports Second Quarter 2023 Financial Results
Moderna | 8-K: Notice of the 2023 Annual Meeting of Stockholders
Moderna | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Moderna | 8-K: Moderna Reports First Quarter 2023 Financial Results
Moderna | DEFA14A: Others
Moderna | DEFA14A: Others
Moderna | DEF 14A: Definitive proxy statements
Moderna | 8-K: Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Moderna | 8-K: Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
Moderna | 8-K: Letter dated January 3, 2023, from Moderna, Inc. to its shareholders
Moderna | 8-K: Moderna and Merck Announce mRNA-4157/V940, in Combination With KEYTRUDA, Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna | 8-K: Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates
Moderna | 8-K: Current report
Moderna | 8-K: Current report
Moderna | 8-K: Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
Moderna | 8-K/A: Current report (Amendment)